37073-15-7

Basic information

• Product Name: 1-(METHYLSULFONYL)-1H-BENZOTRIAZOLE 95
• Synonyms: 1-(METHYLSULFONYL)-1H-BENZOTRIAZOLE 95;1-(METHYLSULFONYL)-1H-BENZOTRIAZOLE 95%;1-(Methylsulfonyl)-1H-benzotriazole;1H-Benzotriazole, 1-(Methylsulfonyl)-;1-(Methylsulfonyl)-1H-benzo[d][1,2,3]triazole;BtMs;1-Methylsulfonylbenzotriazole
• CAS NO: 37073-15-7
• Molecular Formula: C₇H₇N₃O₂S
• Molecular Weight: 197.21438
• Mol File: 37073-15-7.mol
• Article Data: 17

Chemical Properties

• Melting Point: 108-112 °C(lit.)
• Boiling Point: 378.2°C at 760 mmHg
• Flash Point: 182.5°C
• Appearance: /
• Density: 1.54g/cm³
• Vapor Pressure: 6.38E-06mmHg at 25°C
• Refractive Index: 1.698
• Storage Temp.: Sealed in dry,Room Temperature
• Solubility: Chloroform (Slightly), Methanol (Slightly)
• CAS DataBase Reference: 1-(METHYLSULFONYL)-1H-BENZOTRIAZOLE 95(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(METHYLSULFONYL)-1H-BENZOTRIAZOLE 95(37073-15-7)
• EPA Substance Registry System: 1-(METHYLSULFONYL)-1H-BENZOTRIAZOLE 95(37073-15-7)

Safety Data

• Hazard Codes: Xn
• Statements: 22-41
• Safety Statements: 26-36/39
• WGK Germany: 3
• Hazardous Substances Data: 37073-15-7(Hazardous Substances Data)

Usage

Uses

1-Methylsulfonyl-1H-benzotriazole is used as pharmaceutical intermediate.

InChI:InChI=1/C7H7N3O2S/c1-13(11,12)10-7-5-3-2-4-6(7)8-9-10/h2-5H,1H3

Upstream product

• 95-14-7 1,2,3-Benzotriazole 
• 20277-69-4 sodium methansulfinate 
• 124-63-0 methanesulfonyl chloride 
• 43183-36-4 1-(trimethylsilyl)-1H-benzotriazole 

Downstream Products

• 1342801-10-8 1-[1'-(diphenylphosphino)ferrocen-1-carbonyl]-1H-1,2,3-benzotriazole 
• 881902-00-7 (E)-1-(benzotriazol-1-yl)-3-(4-methoxyphenyl)-2-propen-1-one 
• 519054-06-9 (E)-1-Benzotriazol-1-yl-3-(4-nitro-phenyl)-propenone 
• 519054-04-7 (E)-1-(1H-benzo[d][1,2,3]triazol-1-yl)-3-(4-chlorophenyl)prop-2-en-1-one 
• 892875-97-7 (E)-1-(benzotriazol-1-yl)-3-(2-chlorophenyl)-2-propen-1-one 
• 881901-86-6 (E)-1-(benzotriazol-1-yl)-3-(4-methylphenyl)-2-propen-1-one 
• 328012-09-5 (E)-1-(1H-benzo[d][1,2,3]triazol-1-yl)-3-phenylprop-2-en-1-one 
• 1236227-14-7 1,1-dimethylethyl 4-{[(5-{1-[(4-methylphenyl)sulfonyl]-1H-pyrrolo[2,3-b]pyridin-4-yl}-2-thienyl)amino]carbonyl}-4-phenyl-1-piperidinecarboxylate 
• 332021-24-6 1H-1,2,3-benzotriazol-1-yl(4-iodophenyl)methanone 
• 958219-67-5 1-{[6-chloro-2-(3-methoxyphenyl)pyridin-3-yl]acetyl}-1H-1,2,3-benzotriazole 
• 101724-28-1 (2,4-dichlorophenyl)(methanesulfonyl)acetonitrile 
• 38695-60-2 Methyl-<2>thienylsulfon 
• 4231-69-0 1-(4-methoxybenzoyl)-1H-1,2,3-benzotriazole 
• 301164-69-2 (1H-benzo[d][1,2,3]triazol-1-yl)(thiophen-2-yl)methanone 

Relevant articles and documents

Multikilogram Synthesis of a Potent Dual Bcl-2/Bcl-xL Antagonist. 2. Manufacture of the 1,3-Diamine Moiety and Improvement of the Final Coupling Reaction

This paper describes the synthesis of kilogram quantities of the sulfonamide moiety 3 involved in a coupling reaction with acid moiety 2 to provide batches of drug candidate 1 for preclinical studies and first-in-human clinical trials. A first approach relying on a chiral separation furnished the desired enantiomer of 1,3-diamine 20, precursor of sulfonamide 3. An enantiomeric synthesis of 20 using the Ellman's chiral auxiliary coupled with an aza-Reformatsky reaction to control the stereochemistry is also discussed. Coupling conditions of the final step involving EDCI to provide 1 under a cGMP process are detailed. An alternative approach using N-(1-methanesulfonyl)benzotriazole is also presented.

Convenient sulfonylation of benzotriazoles with the in situ–generated sulfonyl bromides

A convenient procedure is developed for the preparation of N-sulfonylbenzotriazoles from sodium sulfinates, benzotriazoles, and sodium bromide in the present of m-chloroperbenzoic acid as oxidant. This radical sulfonylation proceeds efficiently at room te

ENZYME INHIBITORS

The present subject matter relates generally to compounds having the formula (I): wherein each of X, Y, R1, R2, R3, R4, and n are as defined herein. Compounds of formula (I) may act as inhibitors of the thioredoxin reductase enzyme system. The subject matter also relates to use, formulation and preparation of the compounds. The compounds may be useful in the treatment of inflammatory and oxidative diseases and conditions. The compounds may also provide useful anti-proliferative and anti- apoptotic effects.